Why tender forecasting is often underestimated

In many industries, tender business plays a decisive role but nowhere more so than in life sciences and pharma. Large tenders can determine capacity utilisation, inventory levels, service performance, and ultimately profitability for years ahead. Yet despite their strategic importance, tenders are still handled with surprisingly little rigour in most planning processes.

In many organisations, tender volumes are simply ‘probability‑adjusted’ and fed into the demand forecast as if they were just another source of demand. A 50% win probability becomes 50% of the volume. On paper, this looks reasonable. In practice, however, it is often dangerously misleading.

The core issue is not data quality or forecasting skill. It is a fundamental mismatch between how tenders behave and how planning processes are designed to work.

This may sound obvious, yet many planning processes implicitly treat tenders as if they were continuous demand streams. Probability‑weighted volumes create an illusion of precision, but they do not reflect operational reality. You never produce or ship 50% of a tender. You either need full capacity and material readiness – or you need none of it.

This binary nature becomes especially problematic when tender volumes are large relative to the production footprint. In pharma, a single tender can represent an entire production campaign, a full shift, or a meaningful share of annual volume for a product family. Similar patterns appear in private‑label FMCG, process industries, and capital‑intensive manufacturing.

When such tenders are ‘smoothed’ into a forecast, the result is not risk mitigation but risk concealment.